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Abstract 
Objective: The effects of dose-escalation of 5-fluorouracil (5-FU) on the clinical outcome 
and pharmacokinetics of 5-FU were investigated in Japanese patients with Stage III/IVa eso-
phageal squamous cell carcinoma.   
Methods: Thirty-five patients with Stage III/IVa were enrolled, who were treated with a 
definitive 5-FU/cisplatin-based chemoradiotherapy. A course consisted of continuous infu-
sion of 5-FU at 400 mg/m
2/day (the standard dose group, N=27) or 500-550 mg/m
2/day (the 
high dose group, N=8) for days 1-5 and 8-12, infusion of cisplatin at 40 mg/m
2/day on days 1 
and 8, and radiation at 2 Gy/day on days 1 to 5, 8 to 12, and 15 to 19, with a second course 
repeated after a 2-week interval. Plasma concentrations of 5-FU were determined by high 
performance liquid chromatography at 5:00 PM on days 3, 10, 38 and 45, and at 5:00 AM on 
days 4, 11, 39 and 46.   
Results and conclusions: No patient with Stage IVa achieved a complete response in the 
standard dose group, whereas a complete response was observed at a rate of 50% in the 
high dose group, and this can be explained by a higher plasma concentration of 5-FU. The 
circadian rhythm in the concentrations found at the standard dose was not observed for a 
higher dose. 
Key words: esophageal squamous cell carcinoma, 5-fluorouracil, plasma concentration, circadian 
rhythm, dose-escalation 
Introduction 
A clinical report published in 1999, the RTOG 
(Radiation Therapy Oncology Group) 85-01 trial in-
volving 134 patients with T1-3, N0-1 and M0 eso-
phageal cancer, is of great interest in terms of clinical 
outcome because it demonstrated a 5-year survival 
rate of 26 % [1-4]. This treatment consists of a 
96-hr-infusion of 5-fluorouracil (5-FU) at a daily dose 
of 1,000 mg/m2/day in weeks 1, 5, 8 and 11, infusion 
of cisplatin (CDDP) at 75 mg/m2/day on the first day 
of week 1, 5, 8 and 11, and concurrent radiation at 50 Int. J. Med. Sci. 2010, 7 
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Gy in 25 fractions over 5 weeks, without pre- or 
post-surgical resection. The total dose of 5-FU and 
CDDP was 16,000 mg/m2 and 300 mg/m2, respec-
tively. 
Simultaneously in Japan, a dose-reduction ver-
sion was proposed by Ohtsu and his co-workers for 
advanced metastatic esophageal squamous cell car-
cinoma (ESCC) which consists of a 120-hr-infusion of 
5-FU at 400 mg/m2/day in weeks 1, 2, 6 and 7, infu-
sion of CDDP at 40 mg/m 2/day on the first day of 
week 1, 2, 6 and 7, and concurrent radiation at 60 Gy 
in 30 fractions over 8 weeks [5,6]. The total dose of 
5-FU and CDDP was 8,000 mg/m2 and 160 mg/m2, 
respectively, being about half of those in the RTOG 
85-01. Two independent clinical investigations have 
shown curative potential using this regimen for un-
resectable ESCC with T4 or M1a [5,6]. A long-term 
evaluation of efficacy and toxicity with 139 patients 
resulted in a complete response (CR) rate of 56%, 
along with a 5-year survival rate of 29 % [7-9]. Cur-
rently, a definitive 5-FU/CDDP-based chemoradio-
therapy (CRT) is recognized as one of the most 
promising treatments for esophageal cancer [10], and 
future improvements will likely require the modifica-
tion of the RTOG 85-01 regimen or Ohtsu’s regimen, 
and incorporation of a novel anticancer drug.   
A series of studies has been performed to find a 
marker predictive of clinical outcome after treatment 
with the Ohtsu’s regimen [11-13]. A total of 8 meas-
urements of the plasma concentration of 5-FU were 
made per patient, and it was concluded that the av-
erage value was predictive of clinical response, but 
not of severe acute leucopenia, stomatitis and cheilitis 
[13]. The average concentration in the patients with 
CR was 0.122±0.035 μg/mL, and was significantly 
higher than that in non-CR patients, 0.102±0.023 
μg/mL (p = 0.029) [13]. A CR was not observed in 7 
patients with Stage IVa, but the concentration tended 
to be lower in such patients, 0.102±0.028 μg/mL [13], 
suggesting that the dose- escalation of 5-FU results in 
a CR even in the patients with Stage IVa. 
Although little information is available for 
dose-escalation of 5-FU, CDDP or radiation in ad-
vanced esophageal cancer, Yamashita et al. have ap-
plied the RTOG 85-01 protocol [14-17], and two Phase 
II trials, referred to as JCOG (Japan Clinical Oncology 
Group Trial) 9516 and 9407, have been performed for 
advanced ESCC in Japan [18,19]. In this study, based 
on the Ohtsu’s regimen, a dose-escalation of 5-FU 
from 400 mg/m2/day to 500-550 mg/m2/day was 
applied to ESCC patients with Stage III/IVa, and the 
preliminary results are summarized with regard to 
clinical outcome and plasma concentrations of 5-FU.   
Patients and Methods 
Patients 
Thirty-five ESCC patients were enrolled in this 
study, 27 of whom were treated with 400 mg/m2/day 
of 5-FU (the standard dose group), and the remaining 
8 of whom were treated at 500-550 mg/m2/day (the 
high dose group). The patients were recruited based 
on the following criteria: 1) ESCC treated at Kobe 
University Hospital from August 2002 to June 2006; 
2) Stage III (T3/T4, N1, M0) or IVa (T1-T4, N0/N1, 
M1a) according to the International Union Against 
Cancer tumor node metastasis (TNM) classification; 
3) age less than 85 years; 4) an Eastern Cooperative 
Oncology Group performance status of 0 to 2; 5) 
adequate bone marrow, renal, and hepatic function; 
6) no prior chemotherapy; 7) no severe medical com-
plications; and 8) no other active malignancies (except 
early cancer). The tumors were histologically con-
firmed to be primary.   
Protocol  
The protocol is presented in Figure 1. A course 
consisted of continuous infusion of 5-FU at 400 or 
500-550 mg/m2/day for days 1-5 and 8-12, infusion of 
CDDP at 40 mg/m2/day on days 1 and 8, and radia-
tion at 2 Gy/day on days 1 to 5, 8 to 12, and 15 to 19, 
with a second course repeated after a 2-week interval 
[5,6]. If disease progression/recurrence was ob-
served, either salvage surgery, endoscopic treatment, 
or another regimen of chemotherapy was scheduled. 
This study was conducted with the authorization of 
the institutional review board and followed the 
medical research council guidelines of Kobe Univer-
sity.  
Determination of Plasma Concentration of 5-FU 
Aliquots (5 mL) of blood were collected into 
etylenediaminetetraacetic acid-treated tubes at 5:00 
PM on days 3, 10, 38 and 45, and at 5:00 AM on days 
4, 11, 39 and 46 [11-13]. The plasma concentrations of 
5-FU were determined by high-performance liquid 
chromatography as described previously [11-13].   
Clinical Response 
The clinical response was evaluated according to 
the method reported previously [5-9]. Briefly, a CR 
was defined as the complete disappearance of all 
measurable and assessable disease at the first evalua-
tion, which was performed 1 month after the comple-
tion of CRT to determine whether the disease had 
progressed. The clinical response was evaluated by 
endoscopy and chest and abdominal computed to-
mography (CT) scans in each course. A CR at the 
primary site was evaluated by endoscopic examina-Int. J. Med. Sci. 2010, 7 
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tion when all of the following criteria were satisfied 
on observation of the entire esophagus: 1) disap-
pearance of the tumor lesion; 2) disappearance of ul-
ceration (slough); and 3) absence of cancer cells in 
biopsy specimens. If small nodes of 1 cm or less were 
detected on CT scans, the recovery was defined as an 
“uncertain CR” after confirmation of no progression 
for at least 3 months. An “uncertain CR” was in-
cluded as a CR when calculating the CR rate. When 
these criteria were not satisfied, a non-CR was as-
signed. The existence of erosion, a granular pro-
truded lesion, an ulcer scar, and 1.2 w/v% io-
dine/glycerin-voiding lesions did not prevent an 
evaluation of CR. The evaluations were performed 
every month for the first 3 months, and when the cri-
teria for CR were not satisfied at 3 months, the result 
was changed to non-CR. Follow-up evaluations were 
performed thereafter every 3 months for 3 years by 
endoscopy and CT scan. After 3 years, patients were 
seen every 6 months. During the follow-up period, a 
routine course of physical examinations and clinical 
laboratory tests was performed to check the patient’s 
health. 
Severe Acute Toxicities  
A definitive 5-FU/CDDP-based CRT is associ-
ated with acute toxicities; leucopenia, anemia, 
thrombocytopenia, nausea/vomiting, diarrhea, mu-
cositis (including stomatitis), esophagitis, and renal 
dysfunction [5-9, 20]. Here, severe acute leucopenia, 
stomatitis, and cheilitis were subjected into the analy-
sis. Toxicity was evaluated using criteria defined by 
the Japan Clinical Oncology Group [21]. These criteria 
were based on the National Cancer Institute Common 
Toxicity Criteria. Toxicity was assessed on a 2 to 3 
day basis during the CRT and subsequent hospitali-
zation period and on every visit after the completion 
of CRT. Episodes of leucopenia, stomatitis, and 
cheilitis during the first 2 courses and subsequent 2 
weeks (until day 70) were recorded as acute toxicities 
and those of grade 3 or more as severe acute toxici-
ties. 
Data Analysis and Statistics 
All values reported are the mean±standard de-
viation (SD). Circadian variations of plasma concen-
trations of 5-FU were analyzed with the Wilcoxon 
signed-rank test. The unpaired Student’s 
t-test/Welch’s test or Mann-Whitney’s U  test was 
used for two-group comparisons of the concentra-
tions. Fisher’s exact test was used for the analysis of 
contingency tables. P values of less than 0.05 (two 
tailed) were considered to be significant.   
 
 
 
 
 
Figure 1. Protocol of a definitive 5-fluorouracil (5-FU)/ cisplatin (CDDP)-based chemoradiotherapy. One course of 
treatment consisted of protracted venous infusions of 5-FU (400 or 500-550 mg/m
2/day for days 1-5 and 8-12) and CDDP 
(40 mg/m
2/day on days 1 and 8), and radiation (2 Gy/day on days 1-5, 8-12, and 15-19), with a second course (days 36-56) 
repeated after a 2-week interval. 
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Results 
Demographic and clinicopathologic characteris-
tics of the 35 Japanese ESCC patients are summarized 
in Table 1. There was no difference between the 
standard dose group and high dose group, concern-
ing age, height, weight, sex, performance status, dif-
ferentiation, TNM score and clinical stage. Table 2 
shows the results of clinical outcome. The overall CR 
rate was 22.2 % and 37.5 % for the standard dose 
group and high dose group, respectively. In the 
standard dose group, all 6 CR patients were at Stage 
III, and none of Stage IVa patients had a CR. In con-
trast, 2 of 4 Stage IVa patients had a CR in the high 
dose group. Severe acute leucopenia, stomatitis or 
cheilitis were found at a rate of 37.0%, 14.8% and 
18.5%, respectively, and nausea/vomiting and diar-
rhea were found in a few patients (ca. 10%). There 
was no significant increase in the rate of severe acute 
toxicities, according to the increase in the dose of 
5-FU. 
The values of the plasma concentrations of 5-FU 
are listed in Table 3. The average of 8 measurements 
made per patient is listed as the data. The plasma 
concentrations of 5-FU in the high dose group, 
0.137±0.031  μg/mL, were higher than those in the 
standard dose group, 0.112±0.030 μg/mL, but with 
no statistical significance (p = 0.052), presumably due 
to great differences between individuals. In Stage IVa, 
the plasma concentrations of 5-FU in the high dose 
group, 0.144±0.029 μg/mL, were significantly higher 
than those in the standard dose group, 0.101±0.027 
μg/mL (p = 0.028), and tended to be still higher after 
the dose-normalization (0.116±0.012 μg/mL). The 
plasma concentration of 5-FU was 0.131 μg/mL and 
0.182 μg/mL in 2 Stage IVa patients with a CR. 
The circadian variation in the plasma concentra-
tion of 5-FU is shown in Figure 2 and the differences 
between the two groups are summarized in Table 4. 
In the standard dose group, the plasma concentra-
tions of 5-FU at 5:00 AM (0.069±0.031 μg/mL) were 
significantly lower than those at 5:00 PM (0.109±0.059 
μg/mL) in the 1st cycle/1st course (P < 0.05, β = 
0.882) and a similar tendency was observed in the 
2nd cycle/1st course (P = 0.438, β = 0.179), not sig-
nificantly. The plasma concentrations of 5-FU at 5:00 
PM and 5:00 AM in the second cycle were both sig-
nificantly higher than those in the first cycle, and 
these phenomena found in the first course were also 
observed in the second course. As for the high dose 
group, the plasma concentrations of 5-FU at 5:00 AM 
(0.073±0.049 μg/mL) were significantly lower than at 
5:00 PM (0.119±0.043 μg/mL) in the 1st cycle/1st 
course (P < 0.05, β = 0.902), but those at 5:00 AM were 
higher than those at 5:00 PM in the 2nd cycle/1st 
course (not significantly). The plasma concentrations 
of 5-FU at 5:00 PM and 5:00 AM in the second cycle 
were both higher than those in the first cycle. In the 
second course, the circadian variation found in the 
first course was not observed. As shown in Table 4, 
the concentrations in the high dose group were 
higher than those in the standard dose group, but the 
increase was relatively remarkable at 5:00 AM than 
5:00 PM.   
 
Table 1. Demographic and Clinicopathologic Characteris-
tics of 35 Japanese Patients with Esophageal Squamous Cell 
Carcinoma 
Group   Standard 
dose a) 
High 
dose 
p d) 
N 27  8   
Age, yr  63.0±7.8  
(48 -75) b) 
62.5±5.0 
(56 -71) 
0.865 
Height, cm  162.9±7.1 
(150-180) 
164.2±4.6 
(159-172)
0.633 
Weight, kg  55.2±9.3 
(33-79) 
55.3±7.6 
(46-72) 
0.919 
Male/Female 24/3  8/0  1.000 
Performance status, 
0/1/2/unknown 
11/13/2/1 4/4/0/0 1.000 
Differentiation, 
well/moderate/poor/unknown 
3/13/6/5 1/1/3/3 0.266 
T1/T2/T3/T4 1/1/13/12  0/0/6/2 0.655 
N0/N1 3/24  1/7  1.000 
M0/M1a c) 19/8  4/4  0.402 
Stage III/IVa  19/8  4/4  0.402 
a) Standard dose group: 400 mg/m2/day of 5-fluorouracil; High 
dose group: 500-550 mg/m2/day of 5-fluorouracil. 
b) The values are the mean±SD, with the range in parentheses.  
c) Noncervical primary tumors with positive supraclavicular lymph 
nodes were defined as M1a. 
d) Standard dose group vs. high dose group (see the section 
“PATIENTS AND METHODS”). 
 
 
Table 2. Clinical Outcome in 35 Japanese Patients with 
Esophageal Squamous Cell Carcinoma 
Group   Standard 
dose a) 
High 
dose 
p c) 
N 27  8   
Clinical Response       
Complete response (CR) rate b)  6 (22.2 %)   3 (37.5 %)  0.396
Severe Acute Toxicity (Grade 3/4)       
Leucopenia  10 (37.0 %)  4 (50.0 %)  0.685
Stomatitis  4 (14.8 %)   1 (12.5 %)  1.000
Cheilitis  5 (18.5 %)   2 (25.0 %)  0.648
a) Standard dose group: 400 mg/m2/day of 5-fluorouracil; High 
dose group: 500-550 mg/m2/day of 5-fluorouracil. 
b) Two of 4 patients with Stage IVa had a CR in the high dose 
group, but no patient in the standard dose group. 
c) Standard dose group vs. high dose group (Fisher’s exact test). 
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Table 3. Association of Disease Stage with Plasma Con-
centrations (μg/mL) of 5-Fluorouracil in the Standard dose 
and High dose groups.  
Group   Standard  dose  a) High  dose  p c) 
Stage III   19  0.117±0.031 b) 4  0.131±0.036  0.454 
Stage IVa  8  0.101±0.027  4  0.144±0.029  0.028  
Stage III/ IVa  27   0.112±0.030 8  0.137±0.031 0.052 
a) Standard dose group: 400 mg/m2/day of 5-fluorouracil; High 
dose group: 500-550 mg/m2/day of 5-fluorouracil. 
b) The values are the mean±SD. The average of 8 measurements 
made per patient is listed as the data. 
c) Standard dose group vs. high dose group (see the section 
“PATIENTS AND METHODS”). 
 
Table 4. Plasma Concentrations (μg/mL) of 5-Fluorouracil 
in the Standard dose and High dose groups.  
Group Standard  dose  a)  High dose  p c) 
N 27  8   
1st cycle / 1st course       
Day3 5:00 PM  0.109±0.059 b) 0.119±0.043  0.665 
Day4 5:00 AM  0.069±0.031  0.073±0.049  0.758 
2nd cycle / 1st course       
Day10 5:00 PM  0.143±0.053  0.157±0.050  0.515 
Day11 5:00 AM  0.132±0.048  0.170±0.057  0.084 
1st cycle / 2nd course       
Day38 5:00 PM  0.112±0.047  0.134±0.081  0.412 
Day39 5:00 AM  0.073±0.042  0.136±0.058  0.004 
2nd cycle / 2nd course       
Day45 5:00 PM  0.148±0.090  0.158±0.074  0.509 
Day46 5:00 AM  0.115±0.038  0.172±0.090  0.151 
a) Standard dose group: 400 mg/m2/day of 5-fluorouracil; High 
dose group: 500-550 mg/m2/day of 5-fluorouracil. 
b) The values are the mean±SD.  
c) Standard dose group vs. high dose group (see the section 
“PATIENTS AND METHODS”). 
 
 
 
Figure 2. Circadian variation of plasma concentrations of 5-fluorouracil (5-FU) in patients with advanced esophageal cancer. 
A total of 8 measurements were made per patient: 5:00 PM on days 3, 10, 38 and 45, and 5:00 AM on days 4, 11, 39 and 46. 
Closed circle: the standard dose group (N=27), open circle: the high dose group (N=8). The bars represent the SD. * P < 
0.05 in the standard dose group, ** P < 0.05 in the high dose group. 
 
Discussion 
Esophageal cancer is the 8th most common can-
cer in the world and one of the most lethal [10]. 
Symptoms include dysphagia, odynophagia, and 
progressive weight loss. The two predominant histo-
logical subtypes are adenocarcinoma and squamous 
cell carcinoma, and treatment depends on the loca-
tion of the primary tumor, the disease stage, patient 
characteristics and co-morbidities, and occasionally, Int. J. Med. Sci. 2010, 7 
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histological subtype. There is no consensus on an op-
timal treatment strategy for esophageal cancer, and 
treatments include surgical procedures, radiation, 
chemotherapy, and combinations thereof [10]. In pa-
tients with localized squamous cell carcinoma, a de-
finitive 5-FU/CDDP-based CRT is one of the most 
promising ways to achieve a complete pathologic re-
sponse. The treatment might be improved further 
through modification of the treatment schedule, dose 
escalation and the replacement of 5-FU and CDDP.   
Yamashita et al. have demonstrated that the 
RTOG 85-01 regimen is well tolerable for Japanese 
patients, where 44 patients with Stage I/II/III/IV = 
9/9/15/11 were enrolled and the CR rate was 71 % 
[16]. In this study, a dose-escalation of 5-FU from 400 
mg/m2/day to 500-550 mg/m2/day was applied to 
advanced ESCC patients with Stage III/IVa, based on 
Ohtsu’s regimen. The dose was defined according to 
our clinical investigations, and it was found that this 
slight dose escalation is also acceptable for Japanese 
patients. The frequency of severe acute leucopenia 
increased a little. It has been demonstrated that the 
overall CR rate was improved slightly by increased 
amounts of 5-FU. No patient with Stage IVa achieved 
a CR in the standard dose of 5-FU, but 2 of 4 patients 
achieved a CR in the high dose group (Table 2). This 
can be explained by a higher plasma concentration of 
5-FU in the patients (Table 3). It is noted that the con-
centrations were still higher after the 
dose-normalization, suggesting saturation of the 
elimination of 5-FU, especially in Stage IVa. 
Here, it was confirmed that a circadian rhythm 
exists in the concentrations of 5-FU at the standard 
dose (Figure 2). The concentrations were lower in the 
morning than the evening. It is well-known that there 
is a circadian rhythm in drug metabolism, cellular 
proliferation and physiological function, and the su-
prachiasmatic nuclei, a hypothalamic pacemaker 
clock, is important for the rhythm [22-24]. As a result, 
both the toxicity and efficacy of over 30 anticancer 
agents vary as a function of dosing time [22-24]. More 
than 80 % of the administered 5-FU is eliminated by 
the rate-limiting enzyme, dihydropyrimidine dehy-
drogenase (DPD). The DPD activity is found in most 
tissues, but is highest in the liver. The activity of DPD 
of diurnally active cancer patients varies significantly 
during a 24-hour time period, and is greatest from 
midnight to early morning [23-26], being consistent 
with the findings of this study. In addition, it was 
found that the circadian rhythm observed in the pa-
tients treated with the standard dose is not recog-
nized of the higher dose. The DPD activity is inhib-
ited by 5-FU administration [22], and this might con-
tribute to the increase in the concentration of 5-FU in 
the second cycle compared to the first cycle in the 
standard dose group, shown in Figure 2. The disap-
pearance of circadian rhythm in the 5-FU plasma 
concentration of the higher dose can be explained by 
the inhibition of DPD.   
In conclusion, the dose-escalation of 5-FU results 
in a preferable clinical response, especially in ad-
vanced ESCC patients, and this is explained, in part, 
by a higher plasma concentration of 5-FU. The cir-
cadian rhythm found with the standard dose is not 
observed for a higher dose. Chronotherapy of 5-FU is 
believed to be a promising way to optimize cancer 
chemotherapy, and further clinical investigation 
should be performed on the impact of 
dose-escalation, with a large number of patients.   
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